-
Latest News
- EPP self-management courses in North Wales, Jun-July 2019
- Comparison of differential metabolites in urine of the middle school students with CFS before & after exercise
- Altered erythrocyte biophysical properties in CFS
- Webinar: Whole genome sequencing & analysis of ME/CFS, 28 May 2019
- Assessment of the scientific rigour of randomized controlled trials on the effectiveness of cognitive behavioural therapy & graded exercise therapy for patients with ME/CFS: a systematic review
Archives
Tag Archives: Dr Oystein Fluge
B-Lymphocyte depletion in patients with ME/CFS: the final rituximab trial results
B-lymphocyte depletion in patients With Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome: a randomized, double-blind, placebo-controlled trial by Oystein Fluge, Ingrid G. Rekeland, Katarina Lien, Hanne Thurmer, Petter C. Borchgrevink, Christoph Schafer, Kari Sorland, Jorg Assmus, Irini Ktoridou-Valen, Ingrid Herder, Merethe E. … Continue reading
Posted in News
Tagged B-lymphocyte depletion, Dr Oystein Fluge, Dr Peter Rowe, Prof Olav Mella, rituxan, rituximab
Comments Off on B-Lymphocyte depletion in patients with ME/CFS: the final rituximab trial results
Immunosignature analysis of ME/CFS – promising diagnostic biomarker
Immunosignature Analysis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Oliver P Günther, Jennifer L Gardy, Phillip Stafford, Øystein Fluge, Olav Mella, Patrick Tang, Ruth R Miller, Shoshana M Parker, Stephen A Johnston, David M Patrick in Molecular Neurobiology (2018) pp 1-9 [Published online: … Continue reading
Posted in News
Tagged biomarker, diagnostic marker, Dr David Patrick, Dr Oystein Fluge, immune dysfunction, immunosignature, Jennifer L Gardy, Oliver P Günther, Patrick Tang, Phillip Stafford, Prof Olav Mella, Ruth R Miller, Shoshana M Parker, Stephen A Johnston
Comments Off on Immunosignature analysis of ME/CFS – promising diagnostic biomarker
Norwegian rituximab trial reports negative results
The Norwegian Rituximab trial reports negative results ahead of the publication of the full results. Attempts are now under way to determine the best way forward in understanding what has been learned and how to find out which patients may still benefit from … Continue reading
Posted in News
Tagged B-cell, Cort Johnson, Cyclophosphamide, Dr Oystein Fluge, Prof Olav Mella, rituximab, Simmaron Research
Comments Off on Norwegian rituximab trial reports negative results
Norwegian Rituximab studies update
Helse Bergen blog post, 29 Sep 29017: RituxME B-lymphocyte depletion using the anti-CD20 antibody rituximab (Mabthera®) in Myalgic Encephalopathy/Chronic Fatigue Syndrome (“RituxME”) RituxME is a multicentre study conducted in five study centres in Norway: the Oncology Department at Haukeland University … Continue reading
Posted in News
Tagged antibodies, Dr Oystein Fluge, Norway, Prof Olav Mella, rituximab, RituxME
Comments Off on Norwegian Rituximab studies update
Video lectures from English & Norwegian researchers in Norwich
Invest in ME public talks in Norwich on ME/CFS biomedical research, published 7 Feb 2017 An event held in Norwich in January 2017 gave the public a chance to hear about some of the biomedical research being undertaken on the … Continue reading
Posted in News
Tagged Dr Oystein Fluge, Ingrid G Rekeland, Invest in ME, Kari Sorland, Prof Simon Carding, video lecture
Comments Off on Video lectures from English & Norwegian researchers in Norwich
UK Rituximab trial collaboration between Norway & UK featured on BBC
BBC Look East video clip, 26 January 2017: Research in Norwich could offer ME/CFS breakthrough Researchers in Norwich are teaming up with researchers from Norway to collaborate on ME/CFS research. The researchers say they believe that ME is reversible, and … Continue reading
Posted in News
Tagged BBC Look East, Dr Oystein Fluge, Invest in ME, Norway, Norwich, Prof Simon Carding, rituximab, video
Comments Off on UK Rituximab trial collaboration between Norway & UK featured on BBC
